GlassScriptPhysician profile
Rosanne M Sugay
NPI 1205896248
$62,986.93
in general payments reported to CMS, 2019-2025
11 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $540 · 2021: $354 · 2022: $8,408 · 2023: $16K · 2024: $17K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Travel and Lodging: $5,597 · Food and Beverage: $3,447 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,912.50 |
| Travel and Lodging | $5,596.67 |
| Food and Beverage | $3,447.38 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $60,028.38 | 2019-2025 | Biktarvy, Yeztugo, Descovy |
| Viiv Healthcare Company | $1,313.90 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $742.78 | 2019-2025 | |
| Janssen Biotech, INC. | $311.33 | 2019-2021 | |
| Abbvie INC. | $175.80 | 2019-2021 | |
| Melinta Therapeutics, LLC | $150.00 | 2025 | Rezzayo |
| Ferring Pharmaceuticals INC. | $125.89 | 2023 | Rebyota |
| Napo Pharmaceuticals INC | $47.00 | 2019-2023 | Mytesi |
| Aimmune Therapeutics, INC. | $45.71 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $29.50 | 2020-2021 | |
| Astellas Pharma US INC | $16.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosanne Sugay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.